PSB-CB-27
PSB-CB-27 is a potent and selective GPR18 inhibitor with an IC50 of 0.65 μM. PSB-CB-27 shows selectivity over Human GPR55, Human CB1 receptor, and Human CB2 receptor. PSB-CB-27 leads to a complete blockade of Δ9-Tetrahydrocannabinol (THC) -induced GPR18 activation. PSB-CB-27 can be used for inflammatory diseases and cancer immunotherapy research[1].
Product Specifications
CAS Number
[2237222-16-9]
UNSPSC
12352005
Target
Orphan GPCR
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C1N2C(SCCC2)=N/C1=C\C3=CC(OCCCCCCOC4=CC=C(C=C4)Cl)=CC=C3
Molecular Formula
C25H27ClN2O3S
Molecular Weight
471.01
References & Citations
[1]Schoeder CT, et al. Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. Eur J Med Chem. 2018 Jul 15;155:381-397.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
